TRANS-
FORMATION

Unlocked

At Elixir we believe that only by harnessing the power of transformation can there be real-world impact. We are re-imagining how radical medical technologies will breathe new life into vascular interventions, reshaping it for decades to come.

TRANSFORMATION.

TRANS-
FORMA-
TION.

Unlocked.

At Elixir we believe that only by harnessing the power of transformation can there be real world impact. We are re-imagining how radical medical technologies will breathe new life into vascular interventions, reshaping it for decades to come.

We tackle big problems in vascular medicine.

We use transformation as a solution to improve health and quality of life for patients. By disrupting the status quo, we are going where others have given up.

CVDs are leading cause of death

17.9 million lives each year¹

244.1 million

people were living with coronary artery disease²

About 6 million

patients undergo PCI (Percutaneous Coronary Intervention) every year

$407.3 billion

in direct and indirect cost in the United States³

805,000 annual heart attacks in US

200,000 are recurrent³

20% of patients experience an adverse event

within 5 years after PCI procedure⁴

These findings establish that the bioadaptor addresses the shortcomings of DES and bioresorbable scaffolds and collectively point to a technology-effectiveness standard not seen before. The finding of plaque changes is very exciting, pointing to a new effect and potential benefit of restoring vessel function.

DR. SHIGERU SAITO

Our technologies

DynamX coronary bioadaptor

DynamX bioadaptor is a coronary implant that is uniquely designed to not only restore blood flow, but to also unlock and uncage the vessel, allowing the artery to return to its natural physiology, motion and function while DynamX continues to provide dynamic support.

INTRAVASCULAR LITHOTRIPSY

Our novel intravascular lithotripsy catheter uses Hertz Contact Stress to harness the power of physics and mechanics to fracture calcium. Designed with deliverability, safety and simplicity of use in mind.

SITE-SPECIFIC ANTITHROMBOTIC THERAPY

We developed the world’s first site-specific antithrombotic therapy using two anticoagulants (rivaroxaban and argatroban) and an antiproliferative mTOR inhibitor, sirolimus. The technology is designed to address challenges associated with percutaneous coronary intervention (PCI), including management of thrombotic and bleeding risk.

News

ESC Congress 2024: INFINITY-SWEDEHEART Trial of Elixir Medical’s DynamX Bioadaptor Meets Primary Endpoint and Clinical Results Confirm Unique Mechanism of Action

Largest randomized data set to date on bioadaptor, with a complex patient population of 2,400 compared to a DES. Primary endpoint of target lesion failure (TLF) non-inferiority at twelve months was met with a low event rate for DynamX despite increased patient complexity.

Elixir Medical to Present Late-Breaking One-Year Primary Outcomes from the 2,400 Patient INFINITY-SWEDEHEART Clinical Trial at ESC Congress 2024

Elixir Medical is presenting one-year clinical outcomes from the 2,400 patient INFINITY-SWEDEHEART Randomized Clinical Trial (RCT) at ESC Congress 2024 in London.

Elixir Medical’s DynamX Sirolimus-Eluting Coronary Bioadaptor System Granted FDA Breakthrough Device Designation for the Treatment of Symptomatic Ischemic Heart Disease

The designation recognizes the novelty of the technology and the potential to provide a more effective treatment option for patients with coronary artery disease, specifically to improve coronary luminal diameter, restore hemodynamic modulation, and reduce plaque progression in patients with symptomatic ischemic heart disease.

Professor Antonio Colombo, MD

"The bioadaptor is a revolutionary innovation in percutaneous coronary intervention."

Dr. Shigeru Saito

“What sets the bioadaptor apart is that it allows the vessel to move more naturally. I think it does not restrict its natural motion. It is a much more physiologic implant than our traditional stents.”

Dr. Mladen Vidovich

"Although drug-eluting stents (DES) work well for treating coronary artery disease (CAD), they still have limitations even with the latest improvements. It's worth noting that even after five years, more than 20% of patients still experience chest pain or need to return to the hospital, which is a significant number. That's why I'm excited about the bioadaptor technology. It's a new kind of device that's different from traditional stents. This innovative approach can potentially overcome DES's limitations and improve how we treat CAD."

Manh-Hung Pham, MD

"Based on the fact that this device has so many wonderful characteristics and so much positive potential, this is something that every physician should be keen on using in his clinical practice."

Stefan Verheye, MD

"We are grateful to the clinical investigators who ran a world-class randomized controlled trial proving the safety and effectiveness of the DynamX bioadaptor against a leading third-gen DES. The findings of the BIOADAPTOR RCT show the leap-forward in patient care provided by uncaging arteries and continued dynamic vessel support, leading to restoration of motion and function that are critical to improving clinical outcomes for CAD patients."

Vinayak Bhat, PhD

"Drug-eluting stents have been a blessing in the field of interventional cardiology. Nevertheless, the permanent cage, which prevents vessel remodeling, is a limitation. I believe that keeping the vessel as natural as possible is a positive feature (of the bioadaptor)."

Professor Antonio Colombo, MD

“The bioadaptor is a revolutionary innovation in percutaneous coronary intervention.”

Dr. Shigeru Saito

“What sets the bioadaptor apart is that it allows the vessel to move more naturally. I think it does not restrict its natural motion. It is a much more physiologic implant than our traditional stents.”

Dr. Mladen Vidovich

“Although drug-eluting stents (DES) work well for treating coronary artery disease (CAD), they still have limitations even with the latest improvements. It's worth noting that even after five years, more than 20% of patients still experience chest pain or need to return to the hospital, which is a significant number. That's why I'm excited about the bioadaptor technology. It's a new kind of device that's different from traditional stents. This innovative approach can potentially overcome DES's limitations and improve how we treat CAD.”

Manh-Hung Pham, MD

“Based on the fact that this device has so many wonderful characteristics and so much positive potential, this is something that every physician should be keen on using in his clinical practice.”

Stefan Verheye, MD

“We are grateful to the clinical investigators who ran a world-class randomized controlled trial proving the safety and effectiveness of the DynamX bioadaptor against a leading third-gen DES. The findings of the BIOADAPTOR RCT show the leap-forward in patient care provided by uncaging arteries and continued dynamic vessel support, leading to restoration of motion and function that are critical to improving clinical outcomes for CAD patients.”

TRANS-
FORMATION

Unlocked

TRANSFORMATION.

TRANS-
FORMA-
TION.

Unlocked.

We tackle big problems in vascular medicine.

CVDs are leading cause of death

244.1 million

About 6 million

$407.3 billion

805,000 annual heart attacks in US

20% of patients experience an adverse event

Our technologies

DynamX coronary bioadaptor

INTRAVASCULAR LITHOTRIPSY

SITE-SPECIFIC ANTITHROMBOTIC THERAPY

News

ESC Congress 2024: INFINITY-SWEDEHEART Trial of Elixir Medical’s DynamX Bioadaptor Meets Primary Endpoint and Clinical Results Confirm Unique Mechanism of Action

Elixir Medical to Present Late-Breaking One-Year Primary Outcomes from the 2,400 Patient INFINITY-SWEDEHEART Clinical Trial at ESC Congress 2024

Elixir Medical’s DynamX Sirolimus-Eluting Coronary Bioadaptor System Granted FDA Breakthrough Device Designation for the Treatment of Symptomatic Ischemic Heart Disease

References

أجب عن بضعة الأسئلة للتحقق من أعراضك

TRANS-FORMATION

Unlocked

TRANSFORMATION.

TRANS-FORMA-TION.

Unlocked.

We tackle big problems in vascular medicine.

CVDs are leading cause of death

244.1 million

About 6 million

$407.3 billion

805,000 annual heart attacks in US

20% of patients experience an adverse event

Our technologies

DynamX coronary bioadaptor

INTRAVASCULAR LITHOTRIPSY

SITE-SPECIFIC ANTITHROMBOTIC THERAPY

News

ESC Congress 2024: INFINITY-SWEDEHEART Trial of Elixir Medical’s DynamX Bioadaptor Meets Primary Endpoint and Clinical Results Confirm Unique Mechanism of Action

Elixir Medical to Present Late-Breaking One-Year Primary Outcomes from the 2,400 Patient INFINITY-SWEDEHEART Clinical Trial at ESC Congress 2024

Elixir Medical’s DynamX Sirolimus-Eluting Coronary Bioadaptor System Granted FDA Breakthrough Device Designation for the Treatment of Symptomatic Ischemic Heart Disease

"Drug-eluting stents have been a blessing in the field of interventional cardiology. Nevertheless, the permanent cage, which prevents vessel remodeling, is a limitation. I believe that keeping the vessel as natural as possible is a positive feature (of the bioadaptor)."

Professor Antonio Colombo, MD

"The bioadaptor is a revolutionary innovation in percutaneous coronary intervention."

Dr. Shigeru Saito

“What sets the bioadaptor apart is that it allows the vessel to move more naturally. I think it does not restrict its natural motion. It is a much more physiologic implant than our traditional stents.”

Dr. Mladen Vidovich

Manh-Hung Pham, MD

"Based on the fact that this device has so many wonderful characteristics and so much positive potential, this is something that every physician should be keen on using in his clinical practice."

Stefan Verheye, MD

Vinayak Bhat, PhD

References

أجب عن بضعة الأسئلة للتحقق من أعراضك

TRANS-
FORMATION

TRANS-
FORMA-
TION.